The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable non-small cell lung cancer (NSCLC) in adults. NSCLC is the most prevalent form ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab)-based perioperative regimen has been approved by the European Commission (EC) to treat resectable non-small cell lung cancer (NSCLC). The ...

The new indication adds to Imfinzi's FDA-approved indications in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which have helped drive sales of the PD-L1 inhibitor to $1.3 ...

AstraZeneca's PD-L1 inhibitor Imfinzi has become the immunotherapy to be approved in the US for limited-stage small cell lung cancer (LS-SCLC), a particularly challenging form of the disease.

2-Year U.S. Treasury Note Continuous Contract $103.484-0.211-0.20% 5-Year U.S. Treasury Note Continuous Contract $107.398-0.555-0.51% 10-Year U.S. Treasury Note Continuous Contract $109.766-0.828 ...

Mounjaro is available in single-dose vials, with pricing set at Rs3,500 for a 2.5 mg vial and Rs4,375 for a 5 mg vial, leading to a monthly cost of Rs14,000-Rs17,500, depending on dosage.

Finding a good laptop under $500 if anything but an easy task. A quick search for “laptops under $500” into any search bar will flood you with countless results, but most options aren’t ...

Still, Novo would need to offer the drug at a competitive price to Lilly's once-weekly Mounjaro injection, which costs about $50 for a 5 milligram vial, and $40 for a 2.5 mg vial, the lowest doses.

Lilly also claims that PWL actually is charging patients more for the repackaged 2.5-mg vials than it charges for its single-use Zepbound vials through its own LillyDirect program. The lawsuit is ...

Magnificent Seven represent 32% of the S&P 500 as of March 2025, up from 12.3% in 2015. From 2015 to 2024, these seven companies achieved a 697.6% return, outperforming the S&P 500. In 2025 ...